ClinicalTrials.gg
CompletedNCT05414201Updated Jun 10, 2025

A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis

A Phase 4 interventional study of Adalimumab in Non-infectious Intermediate Posterior- or Pan-uveitis, sponsored by AbbVie. Completed at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-10.

Sponsored by AbbVie · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
87
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing adalimumab in Uveitis — 3 open to participants now, 3 under way, 1 of them phase 3. Adalimumab · Uveitis.

Enrollment
7th of 14
87 · median 87
Started
2022
with 1 other
Phase 4
3 of 14
1 open now
Registered
12th of 14
by date
Lead sponsor
2 of 14
AbbVie

Among the 14 studies testing adalimumab in Uveitis, this one is the 7th largest by enrollment, is one of 2 that started in 2022, is one of 3 in phase 4, and was the 12th registered.

Uveitis

300 studies on the registry are indexed under Uveitis; 32 are open to participants now.

Browse Uveitis studies →

Open to participants now

3 of the 14 studies testing adalimumab in Uveitis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 22 Uveitis studies recruiting now, 13 (59%) set no upper age limit and 9 (41%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing adalimumab in Uveitis, or all of them as a file.
02

Study summary

Non-infectious intermediate-, posterior- and pan-uveitis (NIIPPU) are sight threatening diseases with a high patient burden and negative impact on quality of life. Corticosteroids remain the mainstay of first-line treatment for NIIPPU in China despite serious side effects associated with long-term and high-dose corticosteroid use. Adalimumab is used to treat NIIPPU in adults who have had inadequate response to corticosteroids, or who need corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. The purpose of this study is to assess adverse events and effectiveness of adalimumab in Chinese participants requiring high dose corticosteroids with NIIPPU.

Adalimumab is a conditionally approved drug in China used to treat participants with NIIPPU. All participants will receive the same treatment. Approximately 87 adult participants will be enrolled at approximately 15 sites in China.

Participants will receive one subcutaneous loading dose of adalimumab at baseline followed a week later by a lower dose of adalimumab every other week for up to 30 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Non-infectious Intermediate Posterior- or Pan-uveitis

Browse trials for

Keywords

  • Humira
  • Adalimumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female of Chinese descent, with full Chinese parentage.
  • Diagnosed with active non-infectious intermediate uveitis, posterior uveitis, or panuveitis defined by the presence of at least 1 of the following in at least one eye:

    • Active, inflammatory chorioretinal, and/or inflammatory retinal vascular lesion
    • ≥ 2+ anterior chamber cells (Standardization of Uveitis Nomenclature [SUN] criteria); or
    • ≥ 2+ vitreous haze (National Eye Institute [NEI]/SUN criteria).
  • Receiving oral prednisone from ≥ 10mg/day to ≤ 60mg/day (or oral equivalent) for at least two weeks before Screening and remaining on the same dose from Screening to Baseline.

Exclusion criteria

Exclusion Criteria:

  • Participants with the following ocular events:

    • Isolated anterior uveitis;
    • Confirmed or suspected infectious uveitis;
    • Ocular masquerade syndromes, such as ocular lymphoma;
    • Presumed ocular histoplasmosis syndrome;
    • Serpiginous choroidopathy;
    • Scleritis;
    • Corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial;
    • Macular edema as the only sign of uveitis;
    • Severe VH that precludes visualization of the fundus at the baseline visit;
    • Intraocular pressure of ≥ 25 mmHg and on ≥ 2 glaucoma medications or evidence of glaucomatous optic nerve injury;
    • Best Corrected Visual Acuity less than 20 letters Early Treatment Diabetic Retinopathy Study (ETDRS) in either eye at the Baseline visit;
    • Proliferative or severe non-proliferative diabetic retinopathy or macular edema due to diabetic retinopathy;
    • Neovascular/wet age-related macular degeneration;
    • Abnormality of vitreo-retinal interface (i.e., vitreomacular traction, epiretinal membranes, etc.) with the potential for macular structural damage independent of the inflammatory process.
    • Ocular surgery within 90 days prior to the Baseline visit with the exception of refractive laser surgery or retinal laser photocoagulation or YAG (neodymium-doped yttrium aluminium garnet) posterior capsulotomy. These three exceptions are exclusionary within 30 days prior to Baseline.
  • Previous exposure to anti-a TNF therapy inhibitor or any biologic therapy with a potential therapeutic impact on non-infectious uveitis and discontinued for reasons other than lack of efficacy or intolerance (e.g., change of insurance) is allowed after completing the specified prior to the Baseline visit. Participants who have had lack of efficacy or intolerance to TNF inhibitors (including Humira and its biosimilars) are not eligible.
  • Has received glucocorticosteroid implant, Ozurdex® (dexamethasone implant), or intravitreal adalimumab, Methotrexate (MTX) or anti-VEGF therapy at any time prior to the Baseline visit. For those with previous exposure of anti-VEGF therapy, participants must complete the specified wash-out period prior to the baseline visit.
  • Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the baseline visit or oral anti-infectives within 14 days prior to the Baseline visit.
  • Participant has been receiving cyclophosphamide within 30 days and initiated new cyclophosphamide treatment within 30 days prior to the Baseline visit.
  • Participant treated with any drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study.
  • Participant received any with replicating potential within 28 days prior to the first dose of study drug, or expected need of live vaccination with any live vaccine with replicating potential during study participation including at least 70 days after the last dose of study drug. Live vaccines that are incapable of replicating (e.g., JYNNEOS monkeypox vaccine or Convidecia or Convidecia Air COVID-19 vaccines) are permitted.
  • Participant treated with oral traditional Chinese medicine (described for the treatment of UV) within 14 day prior to the first dose of study drug.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Adalimumab

    Participants will receive a loading dose of Adalimumab 80mg SC at Baseline followed a week later by a dose of Adalimumab 40mg SC every other week.

    Drug: Adalimumab

Interventions

  • Subcutaneous Injection

    Also known as: Humira

06

What researchers measure

Primary outcomes

  1. Percentage of participants that achieve quiescence in both eyes

    Quiescence is defined as no active inflammatory chorioretinal and/or inflammatory retinal vascular lesions, anterior chamber (AC) cell grade ≤ 0.5+ and vitreous haze (VH) grade ≤ 0.5+

    Time frame: Week 30

Secondary outcomes

  1. Percentage of participants that achieve no active lesions in both eyes

    Percentage of participants that achieve no active lesions in both eyes.

    Time frame: Week 30

  2. Percentage of participants that achieve Anterior Chamber (AC) cell grade ≤ 0.5+ in both eyes

    Slit lamp examinations will be conducted at each visit to assess AC cell count. The number of AC cells observed within a 1 mm × 1 mm slit beam will be used to determine the grade according to the Standardization of Uveitis Nomenclature (SUN) criteria: Grade 0 = \< 1 cell Grade 0.5+ = 1 - 5 cells Grade 1+ = 6 - 15 cells Grade 2+ = 16 - 25 cells Grade 3+ = 26 - 50 cells Grade 4+ = \> 50 cells.

    Time frame: Week 30

  3. Percentage of participants that achieve Vitreous Haze (VH) grade ≤ 0.5+ in both eyes

    Vitreous haze was measured using dilated indirect ophthalmoscopy (DIO) and assessed by the Investigator according to National Eye Institute (NEI) and SUN criteria: Grade 0: No evident vitreous haze; Grade 0.5+: Slight blurring of the optic disc margin because of the haze; normal striations and reflex of the nerve fiber layer cannot be visualized; Grade 1+: Permits a better definition of both the optic nerve head and the retinal vessels (compared to higher grades); Grade 2+: Permits better visualization of the retinal vessels (compared to higher grades); Grade 3+: Permits the observer to see the optic nerve head, but the borders are quite blurry; Grade 4+: Optic nerve head is obscured.

    Time frame: Week 30

  4. Percentage of participants that achieve no worsening of Best Corrected Visual Acuity (BCVA) by ≥ 15 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) in both eyes

    Using the appropriate corrective lenses based on that visit's refraction, participant's BCVA is measured using an ETDRS chart.

    Time frame: Week 30

  5. Percentage of participants that achieve a ≥ 50% reduction in immunosuppression load

    Achievement of a ≥ 50% reduction in immunosuppression load

    Time frame: Week 30

  6. Percentage of participants that achieve a systemic corticosteriods dose ≤ 7.5 mg

    Achievement of a systemic corticosteriods (CS) dose of ≤ 7.5 mg

    Time frame: Week 30

07

Study locations

7 sites
  • Peking University First Hospital /ID# 243055
    Beijing, Beijing 100034, China
  • Shanghai General hospital /ID# 247252
    Shanghai, Shanghai 200080, China
  • The second affiliated hospital of Zhejiang University school of medicine /ID# 247251
    Hangzhou, Zhejiang 310009, China
  • Eye hospital,WMU Zhejiang Eye Hospital /ID# 247253
    Wenzhou, Zhejiang 325612, China
  • Beijing Tongren Hospital, CMU /ID# 243054
    Beijing, 100730, China
  • Tianjin Medical University Eye Hospital /ID# 243056
    Tianjin, 300384, China
  • Xi'an people's hospital/Xi'an fourth hospital /ID# 243371
    XI An, 710000, China
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Jun 2024, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2022
First posted
Jun 10, 2022
StartActual
Jul 7, 2022
Primary completionActual
Jun 10, 2024
CompletionActual
Jun 10, 2024
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05414201
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 10, 2022
Start date
Jul 7, 2022
Primary completion
Jun 10, 2024
Completion
Jun 10, 2024
Last update
Jun 10, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion